Comparing Two HIV Treatments: Fosamprenavir vs Atazanavir
Author Information
Author(s): Kimberly Y. Smith, Winkler G. Weinberg, Edwin DeJesus, Margaret A. Fischl, Qiming Liao, Lisa L. Ross, Gary E. Pakes, Keith A. Pappa, C. Tracey Lancaster
Primary Institution: Rush University Medical Center
Hypothesis
Is there a difference in efficacy and safety between once-daily fosamprenavir and atazanavir, both boosted with ritonavir, in treating HIV?
Conclusion
Both treatments provided similar results in controlling HIV and improving immune response, but fewer patients on fosamprenavir experienced serious side effects.
Supporting Evidence
- Both treatment regimens achieved similar virologic suppression.
- Fewer patients on fosamprenavir experienced treatment-related grade 2–4 adverse events.
- The study population was diverse in terms of gender, race, and ethnicity.
Takeaway
The study looked at two medicines for HIV and found they worked about the same, but one had fewer bad side effects.
Methodology
This was a randomized, open-label, multicenter study comparing two treatment regimens over 48 weeks.
Potential Biases
Potential bias due to the open-label design.
Limitations
The study had a small sample size and was conducted on a pilot basis.
Participant Demographics
The study included 106 antiretroviral-naïve HIV-infected patients, predominantly male (84%), with a median age of 40 years.
Statistical Information
Statistical Significance
p>0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website